Insights Into Acute Myeloid Leukemia (AML)
Perspectives on management of newly diagnosed and relapsed/refractory AML
Meeting Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Look Inside This Report
Download a sample of this report and start discovering the insights
Report Snapshot
Insights on the following AML therapies were obtained
- azacitidine
- cytarabine and daunorubicin (ie, 7+3)
- decitabine
- ivosidenib
- enasidenib
- gemtuzumab ozogamicin
- gilteritinib
- liposomal daunorubicin and cytarabine
- midostaurin
- sorafenib
- venetoclax
- glasdegib
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- A moderated roundtable discussion focusing on treatment of AML was held on October 26, 2019, in Seattle, WA
- Disease state and data presentations were developed in conjunction with a medical expert from UC Davis
- The group of advisors comprised 10 community oncologists
- Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
